- Home
- XBIT
XBIT
XBiotech Inc.
as of 02-24-2026 4:00pm EST
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 73.2M | IPO Year: | 2015 |
| Target Price: | N/A | AVG Volume (30 days): | 34.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.26 | EPS Growth: | -55.56 |
| 52 Week Low/High: | $2.09 - $3.62 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.88 | Index: | N/A |
| Free Cash Flow: | -32267000.0 | FCF Growth: | N/A |
Compare XBIT vs Leading Stocks
See how XBIT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "XBIT XBiotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.